INTERVIEW WITH JOE O'SULLIVAN
Assessing the Aging Population and Treatment Considerations for Prostate Cancer

INTERVIEW WITH NICHOLAS JAMES
Systemic Therapies for Node-Positive Non-Metastatic Castration Resistant Prostate Cancer

INTERVIEW WITH ROSALIND EELES
Finding the Full Spectrum of Genetic Variants in Advanced Prostate Cancer

INTERVIEW WITH MATTHEW SMITH
Prolonging Time to Metastatic Disease, The SPARTAN Study

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Effects of diabetes on renal cancer prognosis - Session Highlights

ORLANDO, FL USA (UroToday.com) - In this study, Alper Otunctemur and colleagues evaluated the relationship between tumor size and grade with diabetes in patients with renal cancer.

From 2007-2013, the authors enrolled 310 patients who underwent radical nephrectomy for renal cancers in their study. In this patient cohort, they compared fasting glucose levels and HbA1c with respect to tumor size and Fuhrman grade in patients that had diabetes versus those that did not.

auaThe mean age of patients in the study was 64.3 in the diabetes group, while it was 58.4 in the non-diabetic group. The authors found that tumors over 7cm and those with Fuhrman grade 3 or higher were more common in patients with diabetes. Specifically, in the diabetes group, 51% of patients had tumors greater than 7cm in diameter and 53% had higher than 3 Furhman grade 3 tumors. These percentages were found to be lower in the non-diabetes group.

The authors concluded that renal cancer may be more aggressive in patients with diabetes. If these findings are validated in other patient populations, aggressive treatment for diabetes should be studied progressively to see if those patients with more aggressive treatment have lower odds of being diagnosed with renal cancer. It will be useful to have data on the type of medications, such as metformin, the patients in the sample were on. Any diabetes drug can be important covariates in an association of diabetes and renal cell carcinoma.

Presented by Emin Ozbek, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Istanbul, Turkey

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Clinical Congress / October 27 -October 31 / San Francisco, California
  • 2019 Annual Meeting / October 29 - November 2 / Abu Dhabi, United Arab Emirates
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
  • 2019 World Congress / May 1-3 / Liverpool, United Kingdom
Journals
Publications focusing on urologic cancer treatments through original manuscripts
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe